Castle Biosciences (CSTL) Q2 2025: TissueCypher Volume Up 92%, Offsetting SCC Policy Drag

2025-08-04 | By EarningsIQ Research

Castle Biosciences navigated Q2 headwinds with standout 92% volume growth in TissueCypher, compensating for dermatology reimbursement setbacks and driving a guidance raise. Management’s focus on clinical validation and pipeline expansion signals ongoing portfolio diversification, but margin and payer mix pressures remain key watchpoints into 2026.

Summary

• TissueCypher Momentum: Gastroenterology test volumes nearly doubled, fueling guidance increase despite SCC headwinds.
• Portfolio Diversification: Pipeline launches and expanded clinical evidence aim to reduce reimbursement risk concentration.
• Margin Pressure Ahead: Gross margin dilution and payer friction will test operational discipline as mix shifts continue.

Performance Analysis

Castle Biosciences delivered Q2 revenue of $86.2 million, essentially flat year-over-year, as robust growth in non-dermatology tests offset DecisionDx SCC reimbursement losses. While overall test volume increased, the dermatology segment saw a $12.5 million revenue decline, primarily due to the non-coverage policy impacting SCC. In contrast, TissueCypher, the company’s gastroenterology franchise, posted 92% year-over-year test volume growth, driving an $11.7 million revenue gain in non-derm tests.

Gross margin compressed to 77.3%, with adjusted gross margin at 79.5%, reflecting the impact of lower-margin mix and SCC reimbursement disruption. Operating expenses increased across sales, marketing, and G&A, driven by headcount and inflation, while R&D spend moderated as clinical trial activity slowed. Net income fell to $4.5 million from $8.9 million a year ago, and adjusted EBITDA halved to $10.4 million, underscoring the operating leverage challenge as payer mix shifts. Cash flow from operations remained positive, supported by strong test volumes and a disciplined approach to capital deployment.

• Test Volume Divergence: Core drivers grew 33% YoY, but dermatology revenue fell due to SCC policy change.
• Non-Dermatology Surge: TissueCypher’s 92% YoY volume growth provided a critical offset to SCC headwinds.
• Margin Compression: Gross margin declined as mix shifted toward lower-margin tests and SCC reimbursement waned.

Guidance was raised for FY25 revenue, with management now projecting $310–$320 million, up from $287–$297 million previously, reflecting confidence in non-dermatology momentum and continued portfolio expansion.

Executive Commentary

Strategic Positioning

1. Gastroenterology Expansion as Growth Engine

TissueCypher, the GI test franchise, is now the company’s most dynamic growth lever, with volumes up 92% year-over-year. Management attributes this to both unmet clinical need and increased commercial focus, with underpenetration suggesting further room for expansion. The acquisition of Provise and the integration of spatialomics and genomics platforms are aimed at enhancing test accuracy and expanding GI offerings, positioning Castle for multi-modal diagnostic leadership.

2. Dermatology Franchise Faces Payer Risk

DecisionDx SCC revenue fell sharply following the April 2025 non-coverage policy, exposing Castle’s vulnerability to reimbursement concentration. The company submitted reconsideration requests to both Novitas and Moldex, with Novitas already accepting the request as valid. Management’s willingness to continue offering SCC despite reimbursement headwinds underscores a patient-first approach, but also signals near-term gross margin and cash flow pressure as volumes moderate and payer mix remains uncertain.

3. Pipeline and Clinical Evidence Build

Castle is investing in pipeline diversification, notably with an atopic dermatitis test expected to launch by year-end 2025. The company’s collaboration with Sidebase and continued evidence generation (including the largest real-world gene expression study in melanoma) aim to bolster payer negotiations and support future FDA submissions. These efforts are designed to reduce single-product risk and open new reimbursement and market opportunities, though revenue impact from new launches is expected to be immaterial in 2026 and more meaningful in out-years.

4. Commercial Execution and Sales Force Maturation

GI sales rep productivity is reaching maturity, with the full team expected to be at average productivity by Q3/Q4. Management is optimizing commercial resources, with dermatology reps increasingly focused on melanoma as SCC volumes moderate. This operational pivot is intended to maximize return on commercial investments and align resources with growth areas.

5. Disciplined Capital Deployment and M&A Strategy

Castle’s $275.9 million in cash supports ongoing investment in pipeline and select M&A. The company is targeting assets with established reimbursement and clinical synergies, while maintaining a disciplined approach to ensure transactions support near- and mid-term profitable growth. Diversification of both the test portfolio and payer mix remains a priority to mitigate reimbursement risk.

Key Considerations

Castle’s Q2 performance highlights the strategic balancing act between growth, payer risk, and operational discipline. The company is leaning into portfolio diversification and evidence generation to sustain momentum and reduce exposure to reimbursement shocks.

Key Considerations:

• GI Test Underpenetration: TissueCypher’s current growth is driven by both new clinician adoption and increased ordering from existing users, but the GI channel presents unique workflow challenges that may cap ramp speed.
• Reimbursement Uncertainty: SCC policy remains a wildcard; positive reconsideration outcomes could restore dermatology growth, but timing and likelihood are unclear.
• Margin Dilution Risk: As the mix shifts toward lower-margin GI tests, gross margin is likely to remain in the low to mid-70s, even with ongoing cost improvements.
• Pipeline Launch Timing: The atopic dermatitis test and Sidebase collaboration offer long-term optionality, but near-term revenue impact will be limited as reimbursement pathways are established.
• Commercial Payer Resistance: Despite growing clinical evidence, private payer adoption remains slow, requiring continued advocacy and data generation to drive broader coverage.

Risks

Castle faces concentrated reimbursement risk, particularly in the dermatology segment, with ongoing exposure to payer policy shifts and slow-moving commercial coverage. Margin compression is likely as the business mix tilts toward lower-margin GI tests, and operational leverage may be tested if volume growth decelerates or payer mix worsens. Competitive pressures in both dermatology and GI diagnostics, as well as execution risk on pipeline launches and integration of acquired assets, also loom large.

Forward Outlook

For Q3 2025, Castle expects:

• Continued volume growth in TissueCypher and stable melanoma test volumes
• Gross margin trending toward low to mid-70s as SCC reimbursement impact normalizes

For full-year 2025, management raised guidance to:

• $310–$320 million in total revenue

Management emphasized ongoing portfolio expansion, continued clinical evidence generation, and disciplined capital allocation as key drivers for the second half. Watchpoints include SCC reconsideration outcomes, GI sales force productivity, and early pipeline launch execution.

Takeaways

Castle’s Q2 showcased the power of portfolio diversification, as GI test growth offset dermatology reimbursement shocks and enabled a guidance raise. The company’s strategy of doubling down on clinical evidence and pipeline breadth is prudent, but margin and payer mix pressures will require ongoing vigilance and operational discipline.

• GI Franchise Ascendance: TissueCypher’s 92% growth validates the pivot toward underpenetrated GI markets, but workflow and margin challenges remain.
• Reimbursement Volatility: SCC policy drag highlights the need for payer diversification and robust evidence to support future coverage wins.
• Long-Term Optionality: Pipeline launches and multi-modal test development offer upside, but investors should expect gradual revenue inflection as reimbursement and adoption mature.

Conclusion

Castle Biosciences delivered a resilient Q2, leveraging GI momentum and disciplined execution to buffer reimbursement headwinds. As the business mix evolves, success will hinge on payer engagement, margin discipline, and the ability to translate pipeline innovation into durable revenue streams.

Industry Read-Through

Castle’s quarter underscores the importance of portfolio breadth and payer diversification for molecular diagnostics companies facing reimbursement volatility. The rapid growth in GI testing highlights the untapped potential in underpenetrated specialty markets, but also signals that margin dilution is an industry-wide risk as mix shifts away from legacy high-margin franchises. Clinical evidence generation and real-world outcomes data are increasingly essential for both payer negotiations and commercial adoption, setting a higher bar for sustained growth across the diagnostics sector.

CSTL Healthcare Diagnostics Reimbursement Gastroenterology Pipeline Margin